Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | TOP1 | P11387 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9132227 | 0.83 | CA12 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1023894 | 0.78 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL175036 | 0.78 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL4531319 | 0.76 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2525246 | 0.76 | SERPINE1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13286773 | 0.75 | SERPINE1 (0.70) | CA12CA1CA2CA7CA9 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.73 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.73 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL84733 | 0.72 | ARG1 (0.48) | CA1CA2TOP1MAPTKDM4E | |
| SCHEMBL3005634 | 0.71 | ESR1 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, APP | CA12 3773/4885CA1 3723/4885CA2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.